Related Experiment Video

Updated: Jul 16, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

Effects of ICD implantation on quality-adjusted life years in patients with congestive heart failure

Neiko Ozasa, Takeshi Morimoto, Yutaka Furukawa

    International Journal of Cardiology
    |March 21, 2007
    PubMed

    Insights

    Implantable cardioverter-defibrillators (ICDs) may not improve quality-adjusted life years (QALYs) for heart failure patients compared to conventional care. QALYs depend on specific mortality rates and treatment effectiveness, influencing ICD implantation decisions.

    Area of Science:

    • Cardiology
    • Health Economics
    • Decision Science

    Background:

    • Assessing the impact of prophylactic implantable cardioverter-defibrillators (ICDs) on quality-adjusted life years (QALYs) in congestive heart failure (CHF) patients remains unclear.
    • A decision model was created for patients at risk of sudden cardiac death (SCD) with reduced ejection fraction, excluding those with prior life-threatening ventricular arrhythmias.

    Discussion:

    • The model compared QALYs for ICD strategy versus conventional strategy without antiarrhythmic therapies.
    • In a 3-year period, conventional strategy yielded higher QALYs (2.19 years) than ICD strategy (2.14 years).
    • ICD strategy became superior when conventional mortality exceeded 8.6%/year and ICD hazard ratio for death was <0.70.

    Key Insights:

    • Prophylactic ICD implantation may result in lower QALYs compared to conventional management in certain heart failure populations.
    • The decision to implant an ICD is significantly influenced by the inclusion of quality-of-life considerations.
    • Patient-specific factors, particularly mortality risk and treatment efficacy, are critical in optimizing therapeutic choices.

    Outlook:

    • Further research should explore long-term QALY outcomes and cost-effectiveness of ICDs in diverse heart failure subgroups.
    • Integrating patient-reported outcomes and quality of life metrics is crucial for personalized treatment strategies.
    • Refining predictive models for SCD risk stratification will enhance the appropriate selection of ICD candidates.
    Abstract

    More Related Videos

    A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation16:40

    A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

    Published on: February 28, 2012

    Implantation of the Syncardia Total Artificial Heart16:11

    Implantation of the Syncardia Total Artificial Heart

    Published on: July 18, 2014

    Related Concept Videos

    Cardiomyopathy V: Interprofessional Care01:29

    Cardiomyopathy V: Interprofessional Care

    Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
    Heart Failure VI: Adjunct Therapies01:22

    Heart Failure VI: Adjunct Therapies

    Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
    Cardiomyopathy II: Dilated Cardiomyopathy01:30

    Cardiomyopathy II: Dilated Cardiomyopathy

    Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
    Heart Failure IV: Classification and Diagnostic Evaluation01:30

    Heart Failure IV: Classification and Diagnostic Evaluation

    Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
    Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

    Cardiomyopathy III: Hypertrophic Cardiomyopathy

    Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...